Emphysema or COPD, Microbiota, Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Emphysema, Microbiome
Brief summary
Extensive studies suggest composition of microbiome of respiratory samples or lung tissues in COPD patients is different from the composition of healthy smokers. Aim of this study is to analyze composition of microbiome of various samples (e.g. feces, sputum, and urine) and to describe difference of composition between COPD patients and healthy smokers.
Detailed description
After the introduction of the Gut-Lung axis theory, extensive studies revealed diversity of microbiomes among healthy smokers and COPD patients form the respiratory samples or lung tissues. In the previous study, distinct difference in composition of microbiome in lung tissue between healthy smokers and COPD patients was reported. This is a cross sectional study to analyze composition of microbiome of various samples (e.g. feces, sputum, and urine) and to compare difference of composition between COPD patients and healthy smokers. This study would help establishing gut-lung axis model in humans.
Interventions
DIAGNOSTIC_TESTobtain samples from sputum, feces and urine
Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
Sponsors
Asan Medical Center
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Patients with smoking history at least 10 pack-year * Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity ( FEV1/FVC) \<0.7)
Exclusion criteria
* Patients with co-existing illness that would interfere with study results (e.g., malignancy, congestive heart failure, cerebrovascular disorders, chronic renal failure, diabetes with severe complications, or uncontrolled hypertension) * Patients with respiratory disease other than obstructive lung disease (e.g., previous pulmonary resection, tuberculosis-destroyed lung, and bronchiectasis) * Patients with recent (8 weeks prior to screening) exacerbation or other respiratory illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alpha diversity measured by operational taxonomic unit (OTU) quantitative analysis | An average of 1 month | DNA is extracted from each sample from each patient by using a DNA Isolation Kit. The 16S universal primers are used for amplification of 16S ribosomal ribonucleic acid (rRNA) genes with polymerase chain reaction (PCR) system. After amplication, sequencing is performed using the GREENGENES database, after which a metagenomic analysis was performed by the MD Healthcare corporation using MDx-Pro software (Ver.1, Seoul, South Korea). Taxonomic assignment of these sequences is carried out with an operational taxonomic unit (OTU) cutoff of 3%. |
| Microbiome composition by metagenomic analysis | An average of 1 month | The composition of microbiome is presented as bar graph. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biodiversity described by the Shannon diversity index and the Simpson index | An average of 1 month | The Shannon index and the Simpson index is calculated by using metagenomic data. |
| Biodiversity described by Principal Component Analysis (PCA) | An average of 1 month | PCA is performed for all 16S rRNA gene reads clustered at a 97% similarity. |
Countries
South Korea
Contacts
Primary ContactSei Won Lee, M.D. Ph.D.
Outcome results
None listed